FAI

Global Fish Farming Industry Report 2023-2024 & 2029: RAS, IoT Devices and Sensors, Plant-based Feed, Biofloc Technology Emerge as Key Trends - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 30, 2024
Retail, Agriculture, Natural Resources, Food, Beverage, Taste, Partnership, Tilapia, RAS, Salmon, Offshore aquaculture, Environment, COVID-19, Pond, River, Machine learning, Farmer, Aquaculture, AI, Growth, Urbanization, FAI, Bakkafrost, ESR

The global fish farming market value in 2023 stood at US$323.02 billion, and is likely to reach US$444.38 billion by 2029.

Key Points: 
  • The global fish farming market value in 2023 stood at US$323.02 billion, and is likely to reach US$444.38 billion by 2029.
  • The global fish farming market value is projected to grow at a CAGR of 5.46%, during the forecast period of 2024-2029.
  • One of the key drivers behind the growth of fish farming is growing global population and increasing demand for fish protein.
  • Asia Pacific fish farming market enjoyed the highest market share in 2023 and is the fastest growing region as well.

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Retrieved on: 
måndag, maj 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mucositis, FAI, Patient, Mitoxantrone, Survival, Etoposide, Research, AML, Cytarabine, MEC, Incidence, Idarubicin, Acquisition, NCI, Inflammation, Cancer

In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.

Key Points: 
  • In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.
  • Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm.
  • Adverse events were consistent with known side effect profiles of chemotherapy used in the study.
  • The randomized, controlled study is evaluating the addition of uproleselan to a standard cytarabine/daunorubicin regimen (7+3) versus chemotherapy alone.

Record-Setting Verdict Against Uber Technologies Announced by The Law Offices of Brian J. Breiter, LLP

Retrieved on: 
måndag, april 22, 2024
FAI, Shoulder impingement syndrome, Uber, LLP, Personal injury, Communication, Law, Injury, Lyft, Concussion, Private law, Judgement, Seventh Amendment, Lawyer, Accident, Plaintiff, Ridesharing

LOS ANGELES, April 22, 2024 /PRNewswire/ -- The Law Offices of Brian J. Breiter, LLP, proudly announces a groundbreaking verdict against Uber Technologies on April 10, 2024.

Key Points: 
  • LOS ANGELES, April 22, 2024 /PRNewswire/ -- The Law Offices of Brian J. Breiter, LLP, proudly announces a groundbreaking verdict against Uber Technologies on April 10, 2024.
  • For over 5 1/2 years, Uber and the driver denied liability for the accident, with Uber also disputing vicarious liability for the driver's actions.
  • However, on the first day of the trial, Uber stipulated to be vicariously liable for the logged-in driver.
  • The Law Offices of Brian J. Breiter, LLP, with offices in Los Angeles and Miami, provide comprehensive personal injury and wrongful death legal services.

New Study from HSS Reveals Minimally Invasive Procedure Can Delay Arthritis in Select Patients with Hip Impingement

Retrieved on: 
torsdag, april 18, 2024
Pain, Mechanics, FAI, HSS, Hip, Sports medicine, Hospital for Special Surgery, Hospital, Risk, Osteoarthritis, Femoroacetabular impingement, American Journal, Publishing, Research design, MD, Arthroscopy, Hip pain, Research, Arthritis, Patient, Paper, MBA, Philip, FRCS, Joint capsule, Friction, Arthroplasty

NEW YORK, April 18, 2024 /PRNewswire/ -- A new study by surgeon-scientists at Hospital for Special Surgery (HSS) found that 25% of patients with hip impingement who underwent modern arthroscopy for their condition experienced a delay in the natural progression of osteoarthritis. The retrospective study, published online on March 8, 2024, in The American Journal of Sports Medicine, is the first to link hip arthroscopy with a reduced risk of developing hip arthritis over the long term.

Key Points: 
  • Hip impingement occurs when the bones of the hip joint are not shaped properly, causing them to rub against one another.
  • Prior studies have shown that 85-90% of patients with hip impingement who undergo modern arthroscopy return to their usual activity level.
  • "By contrast, we studied the effect of modern arthroscopic methods by comparing the degree of arthritis in each patient's operative hip versus their nonoperative hip.
  • For ideal candidates, the evidence shows that hip arthroscopy may delay or prevent arthritis for one in four patients.

Web3 Goes Borderless: FuturesAI Launches Next-Gen Derivatives Trading Platform

Retrieved on: 
söndag, april 7, 2024
Revolutionary, Friends, AVAX, Dapp, SOL, KYC, AI, Telegraphy, ETH, Partner, FAI, Cryptocurrency

With its innovative approach to futures trading, FuturesAI eliminates barriers, enabling users to trade freely and profitably without the need for cumbersome KYC procedures.

Key Points: 
  • With its innovative approach to futures trading, FuturesAI eliminates barriers, enabling users to trade freely and profitably without the need for cumbersome KYC procedures.
  • In addition to its innovative technology, FuturesAI offers a range of trading utilities and features designed to enhance the trading experience.
  • As for the trading utilities and features, FuturesAI provides:
    Telegram Bot: A cutting-edge Telegram bot that offers a seamless user experience, enabling traders from all corners of the world to engage in crypto derivatives trading.
  • Whether you're a seasoned trader or a newcomer to the world of crypto futures, FuturesAI provides a platform where traders can thrive and succeed.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
måndag, april 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

Retrieved on: 
måndag, april 8, 2024
Cardiovascular disease, Chest pain, Psoriasis, Coronary artery disease, Risk, Inflammation, Patient, Cardiovascular Research, Death, Plaque, Artery, American College, CCTA, Apolipoprotein, Heart, ACC, FAI, Pharmaceutical industry

ATLANTA, April 8, 2024 /PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a pilot, placebo-controlled, randomized clinical trial of Orticumab, a new drug with a novel mechanism of action to combat coronary inflammation, at the American College of Cardiology (ACC) Annual Scientific Sessions in Atlanta. The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.

Key Points: 
  • The trial revealed that treatment with Orticumab during a 15-week period significantly reduced coronary inflammation in patients with psoriasis, who have a higher risk of adverse cardiac events, associated with elevated coronary artery inflammation.
  • Orticumab is a monoclonal antibody against oxidized low-density lipoprotein (oxLDL), a key driver of plaque inflammation and destabilization in coronary artery disease.
  • Abcentra partnered with Caristo Diagnostics to leverage its CaRi-Heart AI technology to measure changes in patients' coronary artery inflammation as result of therapeutic intervention.
  • The results from this trial indicate that targeting oxLDL with Orticumab may reduce residual inflammatory risk and improve outcomes for patients with cardiovascular disease.

Bombardier’s Global 7500 Jet Sets More Than 30 Speed Records, as Precedent-Setting Program Operates Flawlessly Around the World

Retrieved on: 
måndag, mars 25, 2024
Aircraft, Altitude, Filter, Aviation, Record, Mach, Bombardier Global 7500, Atmosphere, Nuage, Safety, Atmosphere of Earth, Catreus, HEPA, Bombardier, FAI, Airline

The Global 7500 also set more than 20 new flight records(1) in the fall of 2023, including routes from Singapore to Anchorage, Alaska and Montreal to Geneva.

Key Points: 
  • The Global 7500 also set more than 20 new flight records(1) in the fall of 2023, including routes from Singapore to Anchorage, Alaska and Montreal to Geneva.
  • The industry-defining Global 7500 jet is equally impressive when it comes to cabin design.
  • It also features the lowest cabin altitude of 2,900 feet when flying at 41,000 ft. – lower than any business jet today.
  • The Global 7500 record from Phoenix to Paris was set by charter firm Phenix Jet Cayman.

Kappa Delta Elizabeth Winston Lanier Award Presented to The ANCHOR Group for Improving Quality of Care for Young Patients With Pre-Arthritic Hip Conditions

Retrieved on: 
fredag, februari 2, 2024
Deformity, BBC, Surgeon, Classification, Research, MD, OA, DDH, Patient, Pain, Safety, Groin, Diagnosis, Adolescence, Orthopedic surgery, Hip, FAI, Femoroacetabular impingement, PAO, Epidemiology, Motion, Quality of life, Data, DSM-IV codes, LCPD, Legg–Calvé–Perthes disease, Health, Data collection, Nursing

This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.

Key Points: 
  • This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.
  • "In the early 2000s, the orthopaedic community lacked an understanding of pre-arthritic hip disease diagnoses and treatments.
  • "Over the past 20 years, access to quality care for young patients with pre-arthritic hip disease has markedly improved" said Dr. Clohisy.
  • "We now have surgeons and health care teams who can deliver a comprehensive approach to manage the full spectrum of pre-arthritic hip disease.

“For the Industry, By the Industry”: CAIA Association Unveils Completely Redesigned Fundamentals of Alternative Investments Program

Retrieved on: 
onsdag, januari 10, 2024
Professional Services, Education, Finance, Asset Management, Continuing, Training, Senior, CAIA, Philosophy, T. Rowe Price, CIPM, Investment, Bank, CFA, Morgan Stanley, Language, Chartered Alternative Investment Analyst, Club, Bank of America, Unifi, FAI, Future, FDP, Advisory Council, Fidelity Investments, Growth, Financial adviser

The Chartered Alternative Investment Analyst (CAIA) Association , the global professional body for the alternative investment industry, is today unveiling a completely redesigned and refreshed Fundamentals of Alternative Investments (FAI) program.

Key Points: 
  • The Chartered Alternative Investment Analyst (CAIA) Association , the global professional body for the alternative investment industry, is today unveiling a completely redesigned and refreshed Fundamentals of Alternative Investments (FAI) program.
  • “The first generation of FAI played a critical role at a time when alternatives were just starting to go mainstream,” said Aaron Filbeck, CAIA, CFA, CFP®, CIPM, FDP, Managing Director, and Head of UniFi by CAIA™.
  • The new FAI is being launched this evening at Unveiling the Future: The Next $20 Trillion in Alternative Investments, Club 101, New York, NY at 5:30pm.
  • “Programs like this will help investment professionals deepen and broaden their understanding of and expertise in the evolving role of private investments in client portfolios.”
    More information on UniFi by CAIA™ can be found here: https://caia.org/programs/unifi